Clinical Trial: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients with Frequent Headaches

This study is not yet open for patient recruitment.
Verified by Allergan September 2005

Sponsored by: Allergan
Information provided by: Allergan Identifier: NCT00168428


This is a 60 week study including a double-blind phase followed by an open-label extension phase.
Condition Intervention Phase
Migraine with frequent headache
 Drug: Botulinum Toxin Type A
Phase III

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further Study Details: 
Primary Outcomes: Frequency of headache episodes
Secondary Outcomes: Frequency of headache days; Frequency of acute headache pain medication use
Expected Total Enrollment:  650


Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • Frequent migraine (>=15 headache days per month)

Exclusion Criteria:

Location and Contact Information

Please refer to this study by identifier  NCT00168428

Allergan Inc.

      Irvine,  California,  United States

More Information

Study ID Numbers:  191622-080
Last Updated:  September 14, 2005
Record first received:  September 12, 2005 Identifier:  NCT00168428
Health Authority: United States: Food and Drug Administration processed this record on 2005-09-20


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us